NeuroOne Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
EDEN PRAIRIE, Minn., May 05, 2023 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders today announced that, effective May 1, 2023, the Compensation Committee of the Board of Directors approved an equity award under the NeuroOne Medical Technologies Corporation 2021 Inducement Plan (the “Inducement Plan”), as a material inducement to one individual entering into employment with the Company. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of awards that are not made under a stockholder approved equity plan.
Related news for (NMTC)
- NeuroOne Medical Technologies Corporation Announces Pricing of $8.0 Million Public Offering of Common Stock
- NeuroOne Medical Technologies Corporation Announces Proposed Public Offering of Common Stock
- NeuroOne® to Report First Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on February 13
- NeuroOne® Reports Fiscal Fourth Quarter and Full Fiscal Year 2023 Financial Results and Provides Corporate Update
- NeuroOne® to Report Second Quarter Fiscal Year 2023 Financial Results and Provide a Corporate Update on May 11